18F-FDG PET/CT可早期预测高危局部进展期直肠癌术前放化疗联合贝伐珠单抗的病理缓解与生存
结果显示早期ΔTLG可区分TRG1与TRG2-TRG5,最佳cutoff为59.5%,且代谢应答者10年PFS和CSS显著更高。
要点
- 早期ΔTLG以59.5%为cutoff预测TRG1,灵敏度80%、特异度71.4%。
- 代谢应答者10年PFS为89.3% vs 63.6%,CSS为92.9% vs 72.6%。
- 晚期代谢评估无法区分TRG1与TRG2-TRG5。
核心结论
- 早期代谢反应可作为抗血管生成治疗获益的替代标志物。
- 早期18F-FDG PET/CT评估有助于预测局部进展期直肠癌术前治疗的病理缓解和生存。
- ΔTLG-early在预测肿瘤退缩方面准确性最佳,可能有助于指导术前放化疗中的治疗调整决策。
研究设计与样本
- 患者接受术前放化疗联合贝伐珠单抗(同期或序贯,放化疗前4天给药)。
- 在基线、放化疗开始后11天(早期)和术前(晚期)行18F-FDG PET/CT。
主要发现
- 早期总病灶糖酵解及其较基线的百分比变化(ΔTLG-early)可区分TRG1与TRG2-TRG5。
- 仅ΔTLG-early的ROC分析显示AUC大于0.7(0.76),最佳cutoff为59.5%(灵敏度80%,特异度71.4%)。
- 晚期代谢评估无法区分TRG1与TRG2-TRG5。
- 中位随访98个月(范围77-132个月)后,代谢应答者(ΔTLG-early≥59.5%)的10年PFS显著更高(89.3% vs 63.6%,P=0.02)。
- 代谢应答者的10年CSS显著更高(92.9% vs 72.6%,P=0.04)。
关键数值与推荐
- ΔTLG-early预测TRG1的AUC为0.76,最佳cutoff为59.5%,灵敏度80%,特异度71.4%。
- 代谢应答定义为ΔTLG-early≥59.5%。
- 代谢应答者10年PFS为89.3% vs 63.6%(P=0.02),10年CSS为92.9% vs 72.6%(P=0.04)。
临床怎么用
- 可在术前放化疗联合贝伐珠单抗早期(开始后11天)行18F-FDG PET/CT评估ΔTLG,辅助预测病理完全缓解和长期生存。
- ΔTLG-early可能用于识别代谢应答者,为术前放化疗期间的治疗调整决策提供参考。
局限性
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is an unmet need for predictive biomarkers of the clinical benefit of antiangiogenic drugs. The aim of the present study was to prospectively evaluate the value of 18F-FDG PET/CT performed during and after preoperative chemoradiotherapy with bevacizumab for the prediction of complete pathologic tumor regression and survival in patients with MRI-defined high-risk locally advanced rectal cancer. Methods: Sixty-one patients treated in a nonrandomized phase II study (BRANCH) with concomitant or sequential (4 d before chemoradiotherapy) administration of bevacizumab with preoperative chemoradiotherapy were included. 18F-FDG PET/CT was performed at baseline, 11 d after the beginning of chemoradiotherapy (early), and before surgery (late). Metabolic changes were compared with pathologic complete tumor regression (TRG1) versus incomplete tumor regression (TRG2-TRG5), progression-free survival, cancer-specific survival, and overall survival. Receiver-operating-characteristic curves were calculated for those 18F-FDG PET/CT parameters that significantly correlated with TRG1. Results: Early total-lesion glycolysis and its percentage change compared with baseline (ΔTLG-early) could discriminate TRG1 from TRG2-TRG5. Only receiver-operating-characteristic analysis of ΔTLG-early showed an area under the curve greater than 0.7 (0.76), with an optimal cutoff at 59.5% (80% sensitivity, 71.4% specificity), for identifying TRG1. Late metabolic assessment could not discriminate between the 2 groups. After a median follow-up of 98 mo (range, 77-132 mo), metabolic responders (ΔTLG-early ≥ 59.5%) demonstrated a significantly higher 10-y progression-free survival (89.3% vs. 63.6%, P = 0.02) and cancer-specific survival (92.9% vs. 72.6%, P = 0.04) than incomplete metabolic responders. Conclusion: Our results suggest that early metabolic response can act as a surrogate marker of the benefit of antiangiogenic therapy. The findings provide further support for the use of early 18F-FDG PET/CT evaluation to predict pathologic response and survival in the preoperative treatment of patients with locally advanced rectal cancer. ΔTLG-early showed the best accuracy in predicting tumor regression and may be particularly useful in guiding treatment-modifying decisions during preoperative chemoradiotherapy based on expected response.
引用
- Avallone A, Aloj L, Pecori B, et al. 18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer. J Nucl Med. 2019. PMID: 30877175. doi:10.2967/jnumed.118.222604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。